HemaSphere (Jun 2022)
P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML
- N. G. Daver,
- P. Montesinos,
- A. Aribi,
- G. Martinelli,
- J. Altman,
- G. Roboz,
- E. S. Wang,
- P. W. Burke,
- D. Jeyakumar,
- R. B. Walter,
- D. J. DeAngelo,
- H. P. Erba,
- A. Advani,
- L. Gastaud,
- X. Thomas,
- E. Todisco,
- N. Pemmaraju,
- L. Mendez,
- A. de la Fuente,
- G. Gaidano,
- A. Curti,
- N. Boissel,
- C. Recher,
- C. Schliemann,
- P. Vyas,
- C. M. Sloss,
- J. Wang,
- K. A. Malcolm,
- P. A. Zweidler-McKay,
- K. L. Sweet
Affiliations
- N. G. Daver
- 1 Department of Leukemia, The University of Texas MD Anderson, Houston, United States of America
- P. Montesinos
- 2 Hospital Universitari i Politècnic La Fe, Valencia, Spain
- A. Aribi
- 3 Gehr Family Center for Leukemia Research, City of Hope, Duarte, United States of America
- G. Martinelli
- 4 Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy
- J. Altman
- 5 Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago
- G. Roboz
- 6 Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York
- E. S. Wang
- 7 Roswell Park Comprehensive Cancer Center, Buffalo
- P. W. Burke
- 8 Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor
- D. Jeyakumar
- 9 University of California Irvine, Chao Family Comprehensive Cancer Center, Orange
- R. B. Walter
- 10 Fred Hutchinson Cancer Research Center, Seattle
- D. J. DeAngelo
- 11 Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston
- H. P. Erba
- 12 Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham
- A. Advani
- 13 Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
- L. Gastaud
- 14 Medical Oncology Department, Antoine Lacassagne Hospital, Nice
- X. Thomas
- 15 Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Lyon, France
- E. Todisco
- 16 Division of Onco-Hematology, European Institute of Oncology IRCCS, Milano, Italy
- N. Pemmaraju
- 1 Department of Leukemia, The University of Texas MD Anderson, Houston, United States of America
- L. Mendez
- 17 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States of America
- A. de la Fuente
- 18 MD Anderson Cancer Center Madrid, Madrid, Spain
- G. Gaidano
- 19 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara
- A. Curti
- 20 IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
- N. Boissel
- 21 Université de Paris, Service Hématologie, Hôspital Saint-Louis, Paris
- C. Recher
- 22 Service d’Hématologie, CHU de Toulouse - Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
- C. Schliemann
- 23 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
- P. Vyas
- 24 MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford NIHR Biomedical Research Centre, and Oxford University Hospitals NHS Trust, Oxford, United Kingdom
- C. M. Sloss
- 25 ImmunoGen, Inc., Waltham
- J. Wang
- 25 ImmunoGen, Inc., Waltham
- K. A. Malcolm
- 25 ImmunoGen, Inc., Waltham
- P. A. Zweidler-McKay
- 25 ImmunoGen, Inc., Waltham
- K. L. Sweet
- 26 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000845108.16448.06
- Journal volume & issue
-
Vol. 6
pp. 454 – 455
Abstract
No abstracts available.